FDA Approves Tislelizumab Plus Chemo for PD-L1+ Unresectable …
Dec 27, 2024 · Key Takeaways Tislelizumab-jsgr (Tevimbra) approved for first-line treatment of HER2-negative gastric or GEJ adenocarcinoma with PD-L1 expression. Phase 3 RATIONALE …
ESCC and GC/GEJC Treatment | TEVIMBRA® (tislelizumab-jsgr)
TEVIMBRA is a prescription medicine used to treat adults with: cancer of the tube that connects your throat to your stomach (esophageal cancer). TEVIMBRA may be used in combination …
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric …
Dec 27, 2024 · “Today’s FDA approval of TEVIMBRA for the treatment of gastric or gastroesophageal junction cancers in PD-L1 positive adult patients marks a significant step …
FDA Approves Tevimbra Combination for Gastric or …
Dec 30, 2024 · A drug called Tevimbra (tislelizumab-jsgr) has been approved for use with chemotherapy as first-line treatment of PD-L1 positive unresectable or metastatic HER2 …
FDA Approves Tislelizumab/Chemo in Gastric/GEJ Adenocarcinoma
Dec 27, 2024 · The News The FDA has approved first-line tislelizumab-jsgr (Tevimbra) plus fluoropyrimidine- and platinum-based chemotherapy for patients with unresectable or …
Tevimbra Approved for Gastric/GEJ Cancer
Dec 27, 2024 · The FDA has approved Tevimbra (tislelizumab) for use in combination with chemotherapy to treat unresectable or metastatic, HER2-, PD-L1+ gastric or GEJ …
BLA for the first-line treatment of adult patients with locally advanced, unresectable, or metastatic gastric or gastroesophageal junction adenocarcinoma (pivotal Study 305, submitted on 28 ...
TEVIMBRA Received FDA Approval as First-Line Therapy for Gastric …
Dec 28, 2024 · The prognosis for patients with gastric or GEJ cancer depends on the stage at diagnosis, treatment response, and overall health. Immunotherapies, such as TEVIMBRA …
FDA Approves Tislelizumab-jsgr (Tevimbra) Combo for Gastric or ...
Dec 30, 2024 · The U.S. Food and Drug Administration approved tislelizumab-jsgr (Tevimbra) in combination with chemotherapy as a first-line treatment for adults with unresectable or …
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric …
Jan 2, 2025 · Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or …